Edition:
United States

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

43.09USD
24 Mar 2017
Change (% chg)

$-0.09 (-0.21%)
Prev Close
$43.18
Open
$43.01
Day's High
$43.85
Day's Low
$42.74
Volume
359,691
Avg. Vol
475,761
52-wk High
$85.83
52-wk Low
$41.60

MNK.N

Chart for MNK.N

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $4,511.29
Shares Outstanding(Mil.): 104.69
Dividend: --
Yield (%): --

Financials

  MNK.N Industry Sector
P/E (TTM): 25.08 29.17 29.94
EPS (TTM): 1.72 -- --
ROI: 1.35 13.48 13.01
ROE: 3.86 14.39 14.16

BRIEF-Mallinckrodt expands share repurchase plan by $1 bln

* Mallinckrodt Plc board expands company's share repurchase plan by $1.0 billion; company announces results of 2017 annual general meeting

Mar 01 2017

BRIEF-Mallinckrodt Plc says co and units entered into refinancing amendment

* Mallinckrodt Plc- on february 28, co and units entered into a refinancing amendment no. 2 and incremental assumption agreement no. 3- sec filing

Mar 01 2017

BRIEF-Mallinckrodt Plc adjusted diluted EPS were $1.91 in transition period

* Mallinckrodt plc reports transition period results and announces 2017 guidance

Feb 07 2017

BRIEF-Mallinckrodt to sell intrathecal therapy business for about $203 mln

* Mallinckrodt to sell intrathecal therapy business to Piramal Enterprises Limited for approximately $203 million

Jan 30 2017

BRIEF-Mallinckrodt completes sale of its Nuclear Imaging Business to IBA Molecular

* Mallinckrodt completes sale of its nuclear imaging business to IBA Molecular for approximately $690 million

Jan 27 2017

Mallinckrodt to pay $100 mln to settle U.S. probe on drug pricing

WASHINGTON Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday.

Jan 18 2017

Mallinckrodt to pay $100 million to settle U.S. probe on drug pricing

WASHINGTON Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday.

Jan 18 2017

UPDATE 2-Mallinckrodt to pay $100 mln to settle U.S. probe on drug pricing

WASHINGTON, Jan 18 Mallinckrodt Plc has agreed to pay $100 million to settle allegations that a subsidiary broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market, the Federal Trade Commission said on Wednesday.

Jan 18 2017

BRIEF-Mallinckrodt, Federal Trade Commission resolve Questcor matter

* Mallinckrodt and Federal Trade Commission resolve Questcor matter

Jan 18 2017

BRIEF-Mallinckrodt CEO Trudeau's FY 2016 total compensation $12.56 mln

* CEO Mark Trudeau's FY 2016 total compensation $12.56 million versus $9.7 million in FY 2015 Source text: (http://bit.ly/2ja4GBS) Further company coverage:

Jan 18 2017

More From Around the Web

Competitors

  Price Chg
Meda AB (MEDAa.ST) -- --
Merck KGaA (MRCG.DE) €103.85 +1.70
AB Science SA (ABS.PA) €16.62 +0.06

Earnings vs. Estimates